Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › ACHIEVE-1

ACHIEVE-1

Orforglipron · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Orforglipron
Population
t2d
Official title
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Sponsor
Eli Lilly and Company
Phase
3
Registry status
completed · 2023-08 → 2025-04
Participants
559
Duration
40 weeks
Registry
NCT05971940

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
orforglipron 36 mgt2d40559−7.9 % vs −1.6 %
Δ −6.3 pp
−7.6 % vs −1.7 %
Δ −5.9 pp
−1.5 vs −0.47.8 vs 1.49.9 vs 7.216.3 vs 2.214.2 vs 1.42.8 vs 3.6—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (8)
  • orforglipron 36 mg · weight_eff · Figure 2B (end-of-curve labels, efficacy estimand; garbled o
    −4.7% (−4.4 kg) −7.9% (−7.3 kg) −1.6% (−1.3 kg) −6.1% (−5.5 kg)
  • orforglipron 36 mg · weight_tp · Results, End Points paragraph; Figure 2A
    −7.6% (95% CI, −8.8 to −6.4) with the 36-mg dose
  • orforglipron 36 mg · ae_dc · Table 2
    Adverse event leading to discontinuation of orforglipron or placebo 8 (5.6) 6 (4.4) 11 (7.8) 2 (1.4) 27 (4.8)
  • orforglipron 36 mg · nausea · Table 2
    Nausea 18 (12.6) 25 (18.2) 23 (16.3) 3 (2.2) 69 (12.3)
  • orforglipron 36 mg · vomiting · Table 2
    Vomiting 7 (4.9) 9 (6.6) 20 (14.2) 2 (1.4) 38 (6.8)
  • orforglipron 36 mg · sae · Table 2
    Any serious adverse event 8 (5.6) 7 (5.1) 4 (2.8) 5 (3.6) 24 (4.3)
  • orforglipron 36 mg · hba1c · Abstract; Results, End Points
    −1.48 percentage points with the 36-mg dose
  • orforglipron 36 mg · disc_any · Results, Participants
    and 504 par- ticipants (90.2%; 129 in the 3-mg group, 120 in the 12-mg group, 127 in the 36-mg group, and 128 in the placebo group) continued to receive orforglipron or placebo throughout the 40-week

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: ACHIEVE-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/achieve-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.